参考文献 [1]Owen DH, Ismaila N, Freeman-Daily J, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1. J Clin Oncol. 2024;42(20):e44-e59. [2]...
参考文献 [1]Owen DH, Ismaila N, Freeman-Daily J, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1. J Clin Oncol. 2024;42(20):e44-e59. [2]Jaiyesimi IA, Leighl NB, Ismaila N, et al. Therapy for Stage IV Non...
Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-...
具有结论有待三期研究进一步验证,期待~参考来源: Xiang M, Yang X, Ren S, Du F, Geng L, Yuan L, Wen Y, Lin B, Li J, Zhang Y, Gang F, Du X. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial. Oncologist...
Updated treatment guidelines for stage IV NSCLCdoi:10.2165/00151234-200905930-00003SpringerPharmacoeconomics & Outcomes News
4、胸腔积液。 治疗经过 经评估患者无手术指征,遂于2022-05-25开始免疫+化疗系统性治疗,方案为:舒格利单抗+紫杉醇+卡铂,辅以止吐、抗过敏治疗,并予噻托溴铵吸入治疗COPD,患者治疗2个周期后(2022-06-15),疗效评估即达到部分缓解(PR),治疗基线时及治疗2个周期后的瘤灶变化情况如图2所示。
[4] KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Aug 10;389(6):491-503 [5] Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant...
The primary end point of overall survival improvement has been reached in the phase 3 LUNAR study, which is evaluating Tumor Treating Fields in combination with standard therapies for the treatment of stage IV non–small cell lung cancer.
1.Wu YL, Zhong WZ, Chen KN, et al. CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR-mutant non–small cell lung cancer[EB/OL]. J Clin Oncol 39, 2021 (suppl 15...
9.Reck M, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020;38 (suppl; abstr 9501). ...